Literature DB >> 18585407

Oligomers of the amyloid-beta protein disrupt working memory: confirmation with two behavioral procedures.

Alan Poling1, Kineta Morgan-Paisley, John J Panos, Eun-Mee Kim, Eugene O'Hare, James P Cleary, Sylvain Lesné, Karen H Ashe, Matthew Porritt, Lisa E Baker.   

Abstract

Converging lines of evidence suggest that oligomers of amyloid-beta play a role in the cognitive impairment characteristic of Alzheimer's disease, but only three studies have provided experimental evidence of such impairment. To provide additional information about the effects of these oligomers on memory, the present study examined the memory of groups of rats exposed to ICV injections of the culture media (CM) of Chinese Hamster Ovary cells that were (7PA2) and were not (CHO-) transfected with a human mutation of amyloid precursor protein that appears to cause early-onset Alzheimer's disease. The 7PA2 CM, which contained concentrations of soluble amyloid-beta oligomers physiologically relevant to those found in human brain, significantly disrupted working memory in rats tested in a radial-arm maze. In contrast, CHO- CM, which did not contain such oligomers, had no effect on memory. The disruptive effects of 7PA2-derived amyloid-beta oligomers, evident 2h after exposure, disappeared within a day. These findings are compared to results from 7PA2 CM tested under a complex procedure thought to measure aspects of executive function. The results confirm the disruptive effects of low-n amyloid-beta oligomers and extend them to a well-established rat model of memory.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18585407      PMCID: PMC2786170          DOI: 10.1016/j.bbr.2008.06.001

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  34 in total

1.  Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease.

Authors:  C A McLean; R A Cherny; F W Fraser; S J Fuller; M J Smith; K Beyreuther; A I Bush; C L Masters
Journal:  Ann Neurol       Date:  1999-12       Impact factor: 10.422

2.  Argyrophilic grain disease: frequency of occurrence in different age categories and neuropathological diagnostic criteria.

Authors:  H Braak; E Braak
Journal:  J Neural Transm (Vienna)       Date:  1998       Impact factor: 3.575

3.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins.

Authors:  M P Lambert; A K Barlow; B A Chromy; C Edwards; R Freed; M Liosatos; T E Morgan; I Rozovsky; B Trommer; K L Viola; P Wals; C Zhang; C E Finch; G A Krafft; W L Klein
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

4.  Intrahippocampal injections of exogenous beta-amyloid induce postdelay errors in an eight-arm radial maze.

Authors:  W A Sweeney; J Luedtke; M P McDonald; J B Overmier
Journal:  Neurobiol Learn Mem       Date:  1997-07       Impact factor: 2.877

5.  Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-beta oligomers.

Authors:  Matthew Townsend; James P Cleary; Tapan Mehta; Jacki Hofmeister; Sylvain Lesne; Eugene O'Hare; Dominic M Walsh; Dennis J Selkoe
Journal:  Ann Neurol       Date:  2006-12       Impact factor: 10.422

Review 6.  The role of cell-derived oligomers of Abeta in Alzheimer's disease and avenues for therapeutic intervention.

Authors:  D M Walsh; I Klyubin; G M Shankar; M Townsend; J V Fadeeva; V Betts; M B Podlisny; J P Cleary; K H Ashe; M J Rowan; D J Selkoe
Journal:  Biochem Soc Trans       Date:  2005-11       Impact factor: 5.407

7.  Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function.

Authors:  James P Cleary; Dominic M Walsh; Jacki J Hofmeister; Ganesh M Shankar; Michael A Kuskowski; Dennis J Selkoe; Karen H Ashe
Journal:  Nat Neurosci       Date:  2004-12-19       Impact factor: 24.884

8.  Soluble beta-amyloid[25-35] reversibly impairs hippocampal synaptic plasticity and spatial learning.

Authors:  Christian Holscher; Simon Gengler; Victor A Gault; Patrick Harriott; Hanspeter A Mallot
Journal:  Eur J Pharmacol       Date:  2007-02-01       Impact factor: 4.432

9.  Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease.

Authors:  L F Lue; Y M Kuo; A E Roher; L Brachova; Y Shen; L Sue; T Beach; J H Kurth; R E Rydel; J Rogers
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

Review 10.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

View more
  28 in total

1.  A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.

Authors:  Sara Landgren; Malin von Otter; Mona Seibt Palmér; Caroline Zetterström; Staffan Nilsson; Ingmar Skoog; Deborah R Gustafson; Lennart Minthon; Anders Wallin; Niels Andreasen; Nenad Bogdanovic; Jan Marcusson; Kaj Blennow; Henrik Zetterberg; Petronella Kettunen
Journal:  J Neural Transm (Vienna)       Date:  2012-05-25       Impact factor: 3.575

2.  Wharton's Jelly-derived mesenchymal stem cells alleviate memory deficits and reduce amyloid-β deposition in an APP/PS1 transgenic mouse model.

Authors:  Zhao-Hong Xie; Zhen Liu; Xiao-Ran Zhang; Hui Yang; Li-Fei Wei; Yun Wang; Shun-Liang Xu; Lin Sun; Chao Lai; Jian-Zhong Bi; Xiao-Yun Wang
Journal:  Clin Exp Med       Date:  2015-07-19       Impact factor: 3.984

3.  An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

Authors:  Oskar Adolfsson; Maria Pihlgren; Nicolas Toni; Yvan Varisco; Anna Lucia Buccarello; Katia Antoniello; Sophie Lohmann; Kasia Piorkowska; Valerie Gafner; Jasvinder K Atwal; Janice Maloney; Mark Chen; Alvin Gogineni; Robby M Weimer; Deborah L Mortensen; Michel Friesenhahn; Carole Ho; Robert Paul; Andrea Pfeifer; Andreas Muhs; Ryan J Watts
Journal:  J Neurosci       Date:  2012-07-11       Impact factor: 6.167

4.  Changes in insulin-signaling transduction pathway underlie learning/memory deficits in an Alzheimer's disease rat model.

Authors:  Xiaojuan Han; Yan Ma; Xiaohui Liu; Lu Wang; Shen Qi; Qinghua Zhang; Yifeng Du
Journal:  J Neural Transm (Vienna)       Date:  2012-04-17       Impact factor: 3.575

5.  The role of STEP in Alzheimer's disease.

Authors:  Pradeep Kurup; Yongfang Zhang; Deepa V Venkitaramani; Jian Xu; Paul J Lombroso
Journal:  Channels (Austin)       Date:  2010-09-06       Impact factor: 2.581

6.  Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease.

Authors:  Mario G Ferruzzi; Jessica K Lobo; Elsa M Janle; Bruce Cooper; James E Simon; Qing-Li Wu; Cara Welch; Lap Ho; Connie Weaver; Giulio M Pasinetti
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model.

Authors:  Aynun N Begum; Fusheng Yang; Edmond Teng; Shuxin Hu; Mychica R Jones; Emily R Rosario; Walter Beech; Beverly Hudspeth; Oliver J Ubeda; Greg M Cole; Sally A Frautschy
Journal:  J Alzheimers Dis       Date:  2008-12       Impact factor: 4.472

8.  Aβ oligomers inhibit synapse remodelling necessary for memory consolidation.

Authors:  Darragh B Freir; Rocio Fedriani; Darren Scully; Imelda M Smith; Dennis J Selkoe; Dominic M Walsh; Ciaran M Regan
Journal:  Neurobiol Aging       Date:  2010-01-25       Impact factor: 4.673

9.  Aβ oligomer toxicity inhibitor protects memory in models of synaptic toxicity.

Authors:  D I C Scopes; E O'Hare; R Jeggo; A D Whyment; D Spanswick; E-M Kim; J Gannon; H Amijee; J M Treherne
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

10.  Alzheimer's disease: synaptic dysfunction and Abeta.

Authors:  Ganesh M Shankar; Dominic M Walsh
Journal:  Mol Neurodegener       Date:  2009-11-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.